SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as its stock experiences a notable post-earnings sell-off despite a blowout report and strong guidance, leading to community discussions centered on alleged market manipulation and "premium harvesting" against the backdrop of ongoing debates about AI sector valuation.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending following a strong Q4 earnings beat, optimistic 2026 revenue guidance, and strategic wins like a new European quantum key distribution network and a spot on the $151 billion SHIELD defense contract, sparking a short squeeze as the community weighs its accelerating growth in quantum infrastructure against profitability concerns.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy is trending after a substantial earnings miss and weak guidance led to a significant stock drop, causing widespread community distrust in management, though some investors see it as an oversold opportunity in the growing energy storage sector.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending as its recent earnings report, featuring a beat on estimates and management's commentary on debt and international growth, triggers intense debate among investors over its perceived extreme undervaluation and the potential for a significant short squeeze.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following its recent earnings, which showed a swing to profitability and an improved outlook, supported by a new non-dilutive credit facility. The community is highly focused on the potential for a significant short squeeze given the high short interest and the strategic value of its Matrix-M adjuvant, especially with new oncology-focused partnerships and the Pfizer collaboration.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending following its strong earnings beat, increased dividend, and the announcement of a massive new share repurchase program, which many in the community view as a strong vote of confidence and a major catalyst. However, a cautious future revenue outlook and ongoing concerns about AI's impact on the software sector are fueling debate among investors.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

UniQure is trending after the FDA indicated that its AMT-130 gene therapy data for Huntington's disease is currently insufficient for a Biologics License Application, leading to intense community debate regarding the FDA's evolving stance on rare disease drug approvals and potential future pathways.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as its strong quarterly earnings beat and robust financials clash with a flat stock performance, leading to investor frustration and calls for CEO Peter Greenleaf's removal due to perceived lack of transparency on the AUR200 pipeline, despite continued speculation about a potential buyout or strategic partnership.

PENN Entertainment, Inc. engages in the provision of integrated entertainment, sports content, and casino gaming services. It operates through the following business segments: Northeast, South, West, Midwest, Interactive, and Other. The Northeast segment includes Ameristar East Chicago, Hollywood Casino, Hollywood Gaming, Marquee, and Plainridge Park Casino operations. The South segment manages 1st Jackpot Casino, Ameristar Vicksburg, Boomtown, Hollywood Casino Gulf Coast, Hollywood Casino Tunica, L’Auberge, and Margaritaville Resort Casino. The West segment is involved in Ameristar Black Hawk, Cactus Petes and Horseshu, M Resort Spa Casino, and Zia Park Casino operations. The Midwest segment focuses on Ameristar Council Bluffs, Argosy Casino, Hollywood Casino, Prairie State Gaming, and River City Casino operations. The Interactive segment refers to an online gaming portfolio which includes ESPN BET, Hollywood Casino, theScore Bet, and PENN Game Studios. The Other segment consists of stand-alone racing operations, namely Sanford-Orlando Kennel Club, Sam Houston, and Valley Race Park. The company was founded by Peter M. Carlino in 1982 and is headquartered in Wyomissing, PA.

PENN Entertainment Inc

PENN Entertainment Inc.

PENN Entertainment is trending following stronger-than-expected Q4 revenue and a notable turnaround in its online gaming division, which achieved positive adjusted EBITDA after rebranding to theScore Bet. The community is actively discussing the optimistic 2026 guidance for its online segment to break even and a new share repurchase program, fueling hopes for a sustained recovery.

Inspire Medical Systems, Inc. is a medical technology company, which focuses on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. The firm offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. It operates through the United States and All Other Countries geographical segments. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.

Inspire Medical Systems Inc

Inspire Medical Systems is seeing heightened trading activity and multiple halts after CMS finalized a rule significantly boosting payment rates for its sleep apnea procedures, effective in 2026, which the community views as a major positive resolution to prior reimbursement uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PTN Novo Nordisk   NVO ▼2.13%  shares fell nearly 13% in pre-market trading today after the company said its next obesity drug did not match Eli Lilly   LLY ▼1.34%  in a head-to-head trial. The update marks a key moment in the fast-growing weight loss drug race, where even small gaps in results can shift market share and investor trust.

JOHNB21400

StockTwits for iOS

Palatin Technologies Inc.

 Novo Nordisk   NVO ▼2.13%  shares fell nearly 13% in pre-market trading today after the company said its next obesity drug did not match Eli Lilly   LLY ▼1.34%  in a head-to-head trial. The update marks a key moment in the fast-growing weight loss drug race, where even small gaps in results can shift market share and investor trust.